Can-Fite BioPharma American Depositary Shares
CANF
7 hedge funds and large institutions have $168K invested in Can-Fite BioPharma American Depositary Shares in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 3 closing their positions.
9.07% less ownership
Funds ownership: 10.41% → 1.34% (-9.1%)
22% less funds holding
Funds holding: 9 → 7 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
95% less capital inflows, than outflows
Capital inflows: $40.2K | Capital outflows: $758K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$40.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$756K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.64K |
| 3 |
Morgan Stanley
New York
|
-$235 |
CANF Hedge Fund Activity: Q2 2023 in Review
7 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q2 2023, worth a combined $168K — down 80% from $844K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CANF and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was RhumbLine Advisers, opening a new position worth an estimated $40.2K. The largest seller was Armistice Capital, exiting entirely with an estimated $756K sold.
- 7 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q2 2023, down from 9 in Q1 2023.
- Funds reported $168K of Can-Fite BioPharma American Depositary Shares stock for Q2 2023, down 80% quarter-over-quarter.
- 1 fund opened new Can-Fite BioPharma American Depositary Shares positions in Q2 2023 and 3 closed out, a net change of -2 holders.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q2 2023 was RhumbLine Advisers, an estimated $40.2K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q2 2023 was Armistice Capital, an estimated $756K sold.
Based on aggregated 13F filings for Q2 2023.